Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evaluation of Epigallocatechin-3-Gallate-Palmitate (EC16) in Nasal Formulations Against Human Coronavirus

Version 1 : Received: 30 March 2023 / Approved: 11 April 2023 / Online: 11 April 2023 (04:55:46 CEST)

How to cite: Frank, N.; Dickinson, D.; Garcia, W.; Xiao, L.; Xayaraj, A.; Lee, L.H.; Chu, T.; Kumar, M.; Stone, S.; Liu, Y.; Yu, H.; Cai, J.; Hsu, S. Evaluation of Epigallocatechin-3-Gallate-Palmitate (EC16) in Nasal Formulations Against Human Coronavirus. Preprints 2023, 2023040192. https://doi.org/10.20944/preprints202304.0192.v1 Frank, N.; Dickinson, D.; Garcia, W.; Xiao, L.; Xayaraj, A.; Lee, L.H.; Chu, T.; Kumar, M.; Stone, S.; Liu, Y.; Yu, H.; Cai, J.; Hsu, S. Evaluation of Epigallocatechin-3-Gallate-Palmitate (EC16) in Nasal Formulations Against Human Coronavirus. Preprints 2023, 2023040192. https://doi.org/10.20944/preprints202304.0192.v1

Abstract

Background: Chronic neurologic diseases are common sequelae of COVID. They severely impact the quality of life and increase the burden on healthcare systems. The long COVID neurological symptoms are due to the robust replication of SARS-CoV-2 in the nasal neuroepithelial cells, leading to neuroinvasion and inflammation of the central nerve system (CNS). Currently used medications and vaccines do not inhibit the robust SARS-CoV-2 replication in the nasal epithelial cells. EGCG-palmitate (EC16), a multifunctional compound, has the potential to become a novel intranasal-delivered drug for minimizing post-COVID neurologic symptoms. Method: EC16-containing formulations were developed and tested in vitro against human β coronavirus OC43 (CoV-OC43) using a TCID50 assay following three test protocols differing in exposure sequence. Results: EC16 formulations in normal saline, phosphate buffered saline, and cell culture medium were found to effectively inhibit human β-coronavirus infection (>99.99%) after a 30-min contact. A single 10-min application to cells after infection (i.e., without direct contact with the virus) resulted in >99% inhibition of viral replication. Conclusion: With its antiviral, antioxidant, anti-inflammatory, and neuroprotective properties, EC16 in nasal formulations could be further developed for clinical applications to COVID-19 patients for minimizing long COVID neurological symptoms.

Keywords

COVID-19; Long COVID; EC16; EGCG-palmitate; Formulations

Subject

Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.